Pharma Latch™ is pleased to offer complimentary access to its advanced intradermal drug delivery device for qualified research partners engaged in pre-clinical studies. This initiative supports innovative therapeutic development by facilitating access to cutting-edge delivery technology designed for precision and consistency.
Get started »
Pharma Latch™ features a proprietary microneedle array platform engineered for parenteral injection directly into the dermis.
Developed to address common challenges in intradermal administration, our device delivers key performance advantages:
Whether you are researching mRNA-based therapeutics, DNA vaccines, immunotherapies, or other molecules that benefit from intradermal targeting, Pharma Latch™ offers a powerful solution for enhancing translational impact.
The Pharma Latch™ device is particularly suited for next-generation biologics that require dermal targeting, including:
If your current research protocols include or are transitioning toward intradermal routes, this platform can help you de-risk early-stage development, improve payload efficiency, and enhance data reliability.
We invite academic laboratories, biotech innovators, and translational researchers to evaluate the Pharma Latch™ system under a technology access agreement. Our scientific team is available to:
By working collaboratively, we aim to accelerate innovation in drug delivery and support your mission to bring new therapies to patients.
Explore the full specifications, device performance metrics, and application data in our downloadable brochure.
Submit a request to receive a complimentary evaluation unit and initiate a conversation with our team.
